Synthetic super-enhancer DNA element in TGX-007 genome (SSE (TGX-007))

The synthetic super-enhancer (SSE) DNA element in the TGX-007 genome is a critical regulatory component of a next-generation oncolytic adenovirus designed for cancer therapy. This engineered DNA sequence is constructed to selectively bind transcription factors that are highly active in cancer cells, thereby driving the robust expression of the viral E1A gene required for replication. By utilizing a synthetic super-enhancer rather than a standard promoter, TGX-007 achieves a higher degree of tumor-specific potency and safety, as the virus can only replicate and induce lysis in cells where the specific oncogenic transcriptional machinery is present. In clinical and preclinical contexts, this element serves as the 'molecular switch' that restricts the therapeutic action of the virus to solid tumors. The design of the SSE is often tailored to exploit the unique epigenetic landscape of various cancers, making it a versatile tool in the development of precision virotherapies.

Other names

Synthetic super-enhancerSSETGX-007 regulatory elementCancer-specific synthetic super-enhancer

The synthetic super-enhancer (SSE) is engineered into the genome of the oncolytic adenovirus TGX-007 to drive the expression of the essential viral gene E1A specifically in cancer cells. By mimicking the high transcriptional activity of natural super-enhancers found in tumors, the SSE ensures that viral replication and subsequent cell lysis occur only within the tumor microenvironment, sparing healthy tissues.